Osiris Therapeutics News

As we close in on expiration at the end of today's session, traders are rolling out positions that they don't want to be without going into Monday.

Last week, the best hope for one of the state's top biotechnology companies became a bust.

StockPreacher.com announces an investment report featuring biotechnology company StemCells Inc.

Osiris Therapeutics Inc. said Friday that its chief financial officer resigned on the same day the company's stem-cell drug candidate Prochymal failed two late-stage studies and the company's stock plunged.

Osiris Therapeutics saw its shares plunge almost 40% in pre-market trading Tuesday after the company said its drug for treating acute graft versus host disease failed a late-stage trial.

Osiris Therapeutics announced that its stem cell drug Prochymal failed both pivotal, phase III studies in patients with graft-versus-host-disease. The stock is currently halted with shares at $12.21. More details to follow.

Posted on August 25th, 2009 at 8:02 by John Sinteur in category: News -- The upshot is fewer new medicines available to ailing patients and more financial woes for the beleaguered pharmaceutical industry.

Aug 6, 2009 - Osiris Therapeutics, Inc. , the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the second quarter of 2009.

Osiris Therapeutics, Inc. today announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures.

Aug 6, 2009 - Osiris Therapeutics, Inc. , the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the second quarter of 2009.

Osiris Therapeutics, Inc. today announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures.

M2 PressWIRE on Tuesday, 28 July 2009 at 18:14 GMT Picksthatmove.com Alerts include Acorda Therapeutics, Inc.

PALO ALTO, Calif.-- --GigOptix Inc. , a leading provider of electronic engines for the optically connected digital world, announces that world renowned electro-optic polymer expert Professor - COLUMBIA, Md.-- --Osiris Therapeutics, Inc.

BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 24, 2009.

Shares of Osiris Therapeutics Inc. fell Wednesday following study results showing the stem-cell drug candidate Prochymal met safety goals but failed to improve lung function in pulmonary disease patients.

Still Positive on Osiris By: Jason Napodano, CFA 0 ) OSIR Share On June 23, 2009, Osiris Therapeutics announced interim results from a phase II trial testing Prochymal as a treatment for chronic obstructive pulmonary disease .

Osiris Therapeutics, Inc. today announced six-month interim data from a Phase II clinical trial evaluating Prochymal, the Company's proprietary formulation of adult mesenchymal stem cells, for the treatment of chronic obstructive pulmonary disease .

CHICAGO-- --Zacks.com announces the list of stocks featured in the Analyst Blog.

Osiris Therapeutics, Inc. , the leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at the Fourth Annual Piper Jaffray Europe Conference in London, UK on ...

Pasadena, CA - 06/17/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has initiated a report on companies who deal in the Adult Stem Cell drug and therapy space.